Примери за използване на May lead to a decrease на Английски и техните преводи на Български
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
This behavior may lead to a decrease in their academic performance.
The combined use of antiarrhythmic drugs with dexamethasone may lead to a decrease in the effect of the latter.
It may lead to a decrease in the number of beta-adrenergic receptors, incl. on lymphocytes.
Deterioration of renal function may lead to a decrease in insulin requirements.
You should not grow Slavia melon in one place for more than two years, as this may lead to a decrease in yield.
These symptoms may lead to a decrease in productivity and affect professional and personal relationships.
For example, some anti-seizure medications,cancer drugs, and steroids may lead to a decrease in bone density.
Injuries to the occiput may lead to a decreased vision, headaches, asthma traumatic genesis, neuroses, depression and much more.
Passage of the next dose of the drug should be avoided, as this may lead to a decrease in therapeutic effectiveness.
This may lead to a decrease in the quality of treatment in the future, and often it turns out that it is impossible to help the patient with anything.
Varicoceles can damage the cells that make testosterone and may lead to a decreased overall testosterone level.
The inflammation may lead to a decrease of vision and/or the presence of floaters in the eye(black dots or wispy lines that move across the field of vision).
Apalutamide is a moderate to strong CYP3A4 inducer and this may lead to a decreased exposure of lopinavir/ritonavir.
Vigabatrin may lead to a decrease in measured plasma activity of alanine aminotransferase(ALT) and to a lesser extent, aspartate aminotransferase(AST).
It should be remembered that an excessive amount of carbon black may lead to a decrease in the strength properties of mortar joint.
VIRACEPT may lead to a decreased AUC of phenytoin; therefore phenytoin concentrations should be monitored during concomitant use with VIRACEPT(see section 4.5).
Working your brain during illness:Working hard or studying with sickness may lead to a decrease in effectiveness of the brain as well as damage the brain.
When initiating treatment with Trulicity, you may in some cases experience loss of fluids/dehydration, e.g. in case of vomiting,nausea and/or diarrhoea which may lead to a decrease in kidney function.
Apalutamide is a moderate to strong CYP3A4 inducer and this may lead to a decreased exposure of ritonavir and potential loss of virologic response.
But the Australian dollar and euro are now at a vulnerable level, anda further decline in risk sentiment may lead to a decrease in these currencies.
Working your brain duringillness- Working hard or studying with sickness may lead to a decrease in effectiveness of the brain as well as damage the brain.
Concomitant administration of other anticonvulsant agents known to be enzymatic inducers(e. g. phenobarbital, carbamazepine)has not been studied but may lead to a decrease in the plasma concentrations of amprenavir.
Intensification of forest management orintensive cultivation of energy crops may lead to a decrease in biodiversity, soil degradation or water stress and pollution(see Box 3).
Varicoceles can damage the cells that make testosterone as well as suppressing their function and may lead to a decreased overall testosterone level.
Co-administration of neomycin orother antibiotics that cause major ecological disturbances of the gastrointestinal microflora may lead to a decrease in sorafenib bioavailability(see section 4.5).
Depolarising muscle relaxant acting medicinal products The concomitant use of amifampridine andmedicinal products with depolarising muscle relaxant effects(e.g. suxamethonium) may lead to a decreased effect of both products and should be taken into consideration.
Anticonvulsant active substances: concomitant administration of anticonvulsant active substances known as enzymatic inductors(phenytoin, phenobarbital, carbamazepine)with amprenavir may lead to a decrease in the plasma concentrations of amprenavir.
Co-administration of ticagrelor with strong CYP3A4 inducers(e.g. rifampicin, dexamethasone, phenytoin, carbamazepine and phenobarbital) is discouraged,as co-administration may lead to a decrease in exposure and efficacy of ticagrelor(see section 4.5).
The drug might lead to a decrease in white blood cells and/or platelets;